StockNews.com Initiates Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)
Equities researchers at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) in a research report issued on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on ADAP. Scotiabank lowered their price objective on Adaptimmune Therapeutics […]
Equities researchers at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) in a research report issued on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on ADAP. Scotiabank lowered their price objective on Adaptimmune Therapeutics […]
